Sleuthing for toxicity Tracey Baas doi:10.1038/scibx.2013.879 Immunocore, Adaptimmune and UPenn researchers have determined that off-target toxicity most likely caused the two fatalities in a cancer trial of affinity-enhanced T cell receptors. The results highlight the need for using biologically appropriate disease models and deep molecular analyses to minimize cross-reactivity–related toxicity in future adoptive immunotherapy trials. Full Text | PDF
Collaborating against diabetes complications Michael J. Haas doi:10.1038/scibx.2013.880 Pfizer's deal with the Sanford-Burnham Medical Research Institute to identify and validate new drug targets to prevent and treat insulin resistance and organ damage in obesity-related diabetes could help reverse a trend that has seen the pharma arriving late—or not at all—to the party with new targets for the indication. Full Text | PDF
Going stromal with docetaxel Chris Cain doi:10.1038/scibx.2013.881 Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that target the tumor stroma and outperform Abraxane in mouse models of breast cancer. The institution is now backing the program with $1.5 million to bring it to the clinic. Full Text | PDF
DISCerning schizophrenia in mice C. Simone Fishburn doi:10.1038/scibx.2013.882 A team at The Johns Hopkins University has created a transgenic mouse model of prefrontal dysfunction involving disrupted networks of neurons that cause behavioral changes similar to those seen in patients with schizophrenia or mood disorders. Full Text | PDF
Natural killer p30 receptor (NKp30;NCR3; CD337) doi:10.1038/scibx.2013.883 Patient studies suggest inhibiting NKp30 could help treat the autoimmune disease primary Sjögren's syndrome (pSS). Full Text | PDF
Phosphoinositide kinase FYVE finger containing (PIKFYVE) doi:10.1038/scibx.2013.884 Cell culture studies identified the molecular target of apilimod as PIKFYVE, suggesting the target could be inhibited to treat autoimmune diseases. Full Text | PDF
Actin α2 smooth aorta muscle (ACTA2; α-SMA) doi:10.1038/scibx.2013.885 Mouse studies suggest a polyethylene glycol formulation of docetaxel conjugated to acetylated carboxymethylcellulose could help treat breast cancer. Full Text | PDF
Mediator of cell motility 1 (MEMO1; MEMO) doi:10.1038/scibx.2013.886 Mouse and cell culture studies suggest inhibiting MEMO could help treat estrogen-dependent breast cancers. Full Text | PDF
Androgen receptor; cyclin D1 (CCND1; BCL1) doi:10.1038/scibx.2013.887 In vitro and mouse studies identified acetamide analog small molecules that could help treat prostate and other cancers. Full Text | PDF
Cyclic adenosine monophosphate (cAMP); cell division cycle 25B (CDC25B); melanocortin 1 receptor (MC1R) doi:10.1038/scibx.2013.888 Cell culture studies suggest targeting the MC1R-cAMP-CDC25B signaling pathway could help treat melanoma. Full Text | PDF
Proteasome doi:10.1038/scibx.2013.889 In vitro and mouse studies identified a homopiperazine proteasome inhibitor that could help treat drug-resistant MM. Full Text | PDF
Regenerating islet-derived 3β (REG3B) doi:10.1038/scibx.2013.890 Mouse studies suggest inhibiting REG3B could help treat pancreatic cancer. Full Text | PDF
Potassium channel K2p3.1 (KCNK3); phospholipase A2 (PLA2) doi:10.1038/scibx.2013.891 Studies in patient samples and cell culture suggest activating KCNK3 could help treat pulmonary arterial hypertension (PAH). Full Text | PDF
IL-15; IL-15 receptor α-chain (IL-15RA) doi:10.1038/scibx.2013.892 Studies in mice and human samples suggest inhibiting IL-15 or IL-15RA could help treat type 1 diabetes. Full Text | PDF
Not applicable doi:10.1038/scibx.2013.893 Mouse studies suggest the nucleotide sugar uridine diphosphate glucose (UDP-glucose) could be useful for stem cell mobilization in potential bone marrow donors. Full Text | PDF
Not applicable doi:10.1038/scibx.2013.894 Rat studies suggest decreasing mitochondrial reactive oxygen species could help prevent kidney damage in acute infectious pyelonephritis. Full Text | PDF
Transforming growth factor-β1 (TGFB1); transforming growth factor-β receptor 1 (TGFBR1; ALK5); TGFBR2 (TGFβ-RII) doi:10.1038/scibx.2013.895 Studies in human samples suggest inhibiting TGFBR1 or TGFBR2 could help treat allergy-related conditions. Full Text | PDF
Heparan sulfate glycosaminoglycan (HSGAG) doi:10.1038/scibx.2013.896 In vitro studies identified heparan sulfate mimetics that could help treat inflammatory diseases. Full Text | PDF
β-Amyloid (Aβ) doi:10.1038/scibx.2013.897 In silico and in vitro studies identified Aβ fiber–binding compounds that could help treat AD. Full Text | PDF
Liver X receptor-β (NR1H2; LXR-β) doi:10.1038/scibx.2013.898 SAR and mouse studies suggest flavonoid LXR-β agonists could be useful for treating AD. Full Text | PDF
Fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS) doi:10.1038/scibx.2013.899 Mouse studies suggest inhibiting FUS aggregation could help treat ALS. Full Text | PDF
Microtubule-associated protein-τ (MAPT; TAU; FTDP-17) doi:10.1038/scibx.2013.900 Mouse studies suggest inhibiting TAU protein could help prevent seizures. Full Text | PDF
Low-density lipoprotein-related protein 1 α-2-macroglobulin receptor (LRP1; CD91); neurotrophic tyrosine kinase receptor 3 (NTRK3; TrkC) doi:10.1038/scibx.2013.901 Cell culture and rat studies suggest targeting LRP1 could promote neuronal regeneration. Full Text | PDF
Tumor necrosis factor-α (TNF-α) doi:10.1038/scibx.2013.902 Biochemical and cell culture studies identified a bicyclic peptide inhibitor of TNF-α that could help treat cachexia and autoimmune disease. Full Text | PDF
Nanometer-scale thermometry in living cells doi:10.1038/scibx.2013.903 Nanometer-scale thermometry in living cells could be useful for monitoring cellular activity in response to stimuli and could aid the development of temperature-sensitive therapeutics. Full Text | PDF
Phenotypic neuronal assays to screen for small molecules that decrease β-amyloid (Aβ) doi:10.1038/scibx.2013.904 Phenotypic screening of embryonic stem cell (ESC)-derived neurons could help identify small molecules that decrease Aβ to treat Alzheimer's disease (AD). Full Text | PDF
Strategy to decrease off-target peptide recognition by affinity-enhanced, T cell receptor (TCR)-based T cell therapies doi:10.1038/scibx.2013.905 Amino acid scanning and cell culture screens could be used to decrease the risk of off-target toxicity from TCR-based T cell therapies to treat cancer. Full Text | PDF
Mouse model of fibroblast growth factor 9 (Fgf9; Gaf)-driven lung cancer doi:10.1038/scibx.2013.906 Transgenic mice with inducible expression of Fgf9 in lung epithelium could be useful as a model to help identify new treatments for lung cancer. Full Text | PDF
Mouse model of methylmalonic acidemia–associated renal pathology doi:10.1038/scibx.2013.907 A mouse model of methylmalonic acidemia–associated renal pathology could help identify new treatments for the condition, which is a metabolic disorder caused primarily by mutations in methylmalonyl CoA mutase (MUT). Full Text | PDF
Mouse models of idiopathic basal ganglia calcification (IBGC) doi:10.1038/scibx.2013.908 Mouse models of IBGC could be useful for studying associations between brain lesions and cognitive, motor and psychiatric symptoms. Full Text | PDF
Rat model of Roux-en-Y gastric bypass doi:10.1038/scibx.2013.909 Roux-en-Y gastric bypass–treated rats could be used to study the mechanisms underlying the efficacy of the procedure and could help develop new treatments for metabolic diseases. Full Text | PDF
Lentiviral vectors targeting endoglin (CD105; ENG) for endothelial cell–targeted therapy doi:10.1038/scibx.2013.910 In vitro and mouse studies suggest lentiviral vectors targeting CD105 could be used for endothelium-targeted gene delivery. Full Text | PDF
Crystal structure of glucagon receptor (GCGR) doi:10.1038/scibx.2013.911 A crystal structure of GCGR could help drug discovery efforts targeting class B GPCRs. Full Text | PDF
Photoreceptor replacement therapy for degenerative retinal disease doi:10.1038/scibx.2013.912 Embryonic stem cell (ESC)-derived photoreceptors could help treat degenerative retinal diseases. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment
Keep a civil tongue.